Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Implementation of 3HP versus 9H for latent tuberculosis infection in Darwin
ACTRN12619001704189Phase 4Completed
- Sponsor
- Northern Territory Centre for Disease Control
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of isoniazid and rifapentine in latent tuberculosis infection (LTBI) (2 arms), sponsored by Northern Territory Centre for Disease Control. Primary endpoint: Treatment completion rate. Started Oct 2021; status: completed.
02
Drugs
isoniazidrifapentine
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on ACTRN12619001704189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001704189.